Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL),
(‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing medicinal
cannabinoid and psychedelic therapies for unmet medical needs, is delighted to announce that it has
engaged multinational contract development and manufacturing organisation (CDMO) Eurofins
Scientific (‘Eurofins’) to manufacture Incannex’s two distinct medicated chewable products designed to
treat nicotine and opioid addiction disorders.

The CannQuit products are combination drug assets with associated granted patents and patent
applications that were transferred to Incannex as a result of the acquisition of APIRx Pharmaceuticals,
completed in August of 2022. Eurofins will undertake formulation development and manufacture of
CannQuit Nicotine (‘CannQuit-N’) and CannQuit Opioid (‘CannQuit-O’).